IN2012DN00733A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00733A
IN2012DN00733A IN733DEN2012A IN2012DN00733A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A IN 733DEN2012 A IN733DEN2012 A IN 733DEN2012A IN 2012DN00733 A IN2012DN00733 A IN 2012DN00733A
Authority
IN
India
Prior art keywords
polypeptides
medicaments
well
relates
present
Prior art date
Application number
Inventor
Fred Hofmann
Jurgen Frevert
Original Assignee
Merz Pharma Gmbh & Co Kgaa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merz Pharma Gmbh & Co Kgaa filed Critical Merz Pharma Gmbh & Co Kgaa
Publication of IN2012DN00733A publication Critical patent/IN2012DN00733A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1282—Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Mycology (AREA)
  • Birds (AREA)
  • Toxicology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Surgery (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The present invention relates to the pharmaceutical field. Specifically, it contemplates a polynucleotide encoding a Neurotoxin polypeptide exhibiting a reduced duration of the biological effect in a subject, wherein said polypeptide comprises a at least one degradation signal in the light chain as well as vectors and host cells comprising the said polynucleotide, polypeptides encoded thereby and antibodies specifically binding to the polypeptides. Moreover, the invention relates to medicaments comprising said polynucleotides and polypeptides as well as specific therapeutic applications thereof. Furthermore, the present invention contemplates methods for the manufacture of the polypeptides and medicaments..
IN733DEN2012 2009-07-02 2010-07-01 IN2012DN00733A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27019809P 2009-07-02 2009-07-02
EP09164365 2009-07-02
PCT/EP2010/059398 WO2011000929A1 (en) 2009-07-02 2010-07-01 Neurotoxins exhibiting shortened biological activity

Publications (1)

Publication Number Publication Date
IN2012DN00733A true IN2012DN00733A (en) 2015-06-19

Family

ID=40911088

Family Applications (1)

Application Number Title Priority Date Filing Date
IN733DEN2012 IN2012DN00733A (en) 2009-07-02 2010-07-01

Country Status (14)

Country Link
US (4) US8586329B2 (en)
EP (1) EP2449101B1 (en)
JP (2) JP6059986B2 (en)
KR (2) KR20120104140A (en)
CN (1) CN102471765B9 (en)
AU (1) AU2010267963B2 (en)
BR (1) BRPI1014253A2 (en)
CA (1) CA2763692A1 (en)
ES (1) ES2693705T3 (en)
IL (1) IL216414A (en)
IN (1) IN2012DN00733A (en)
MX (2) MX2011013014A (en)
RU (1) RU2582266C2 (en)
WO (1) WO2011000929A1 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19925739A1 (en) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutic with a botulinum neurotoxin
AR061669A1 (en) * 2006-06-29 2008-09-10 Merz Pharma Gmbh & Co Kgaa HIGH FREQUENCY THERAPY APPLICATION WITH BOTULIN TOXIN
US9746475B2 (en) 2011-03-14 2017-08-29 University Of Southern California Antibody and antibody mimetic for visualization and ablation of endogenous proteins
BR112014011137A2 (en) * 2011-11-09 2018-06-12 Merz Pharma Gmbh & Co Kgaa polynucleotide, vector, host cell, polypeptide, antibody, method for making a polypeptide, method for making a drug
EP2885316A1 (en) 2012-08-20 2015-06-24 Merz Pharma GmbH & Co. KGaA Novel method for the manufacturing of recombinant proteins harbouring an n-terminal lysine
EA027277B1 (en) 2012-10-16 2017-07-31 Альмираль, С.А. Pyrrolotriazinone derivatives as pi3k inhibitors
CA2880897C (en) 2012-11-21 2020-01-14 Ipsen Bioinnovation Limited Methods for the manufacture of proteolytically processed polypeptides
ES2704677T3 (en) 2013-04-18 2019-03-19 Fond Telethon Efficient supply of large genes by dual AAV vectors
EP2952205B1 (en) 2014-06-06 2017-08-09 Kleiner-Fisman, Galit Botulinum toxin for use in the treatment of paratonia
WO2015188943A1 (en) 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Use of recombinant clostridial neurotoxins for the treatment of patients having certain muscle-related disorders
US20170112907A1 (en) 2014-06-13 2017-04-27 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
US20170119863A1 (en) * 2014-06-13 2017-05-04 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
WO2015188942A1 (en) * 2014-06-13 2015-12-17 Merz Pharma Gmbh & Co. Kgaa Novel uses of recombinant clostridial neurotoxins with decreased duration of effect
ES2788999T5 (en) 2014-12-23 2025-02-24 Merz Pharma Gmbh & Co Kgaa Botulinum toxin prefilled container
PT3242884T (en) 2015-01-09 2021-04-22 Ipsen Bioinnovation Ltd Cationic neurotoxins
MX2017011255A (en) * 2015-03-03 2018-08-01 Fond Telethon Multiple vector system and uses thereof.
US20180128830A1 (en) * 2015-04-16 2018-05-10 Juliet V. Spencer Detection of human cytomegalovirus in breast cancer
TW201718627A (en) 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 Recombinant clostridial neurotoxin, a use thereof, and a method for generating the same, a pharmaceutical composition comprising the same and a precursor corresponding to the same, a nucleic acid sequence encoding the precursor and a method for obtaining
KR101793328B1 (en) * 2015-07-03 2017-11-03 씨제이제일제당 (주) A microorganism having enhanced L-lysine productivity and a method of producing L-lysine using the same
WO2017063743A1 (en) 2015-10-14 2017-04-20 Merz Pharma Gmbh & Co. Kgaa Improvements to ultrasound-based therapy of photoaged tissue
SG11201805195YA (en) 2016-03-02 2018-07-30 Merz Pharma Gmbh & Co Kgaa Composition comprising botulinum toxin
CN114689870B (en) * 2016-06-02 2025-02-18 朋友股份有限公司 Egg allergic antigen
TWI737742B (en) 2016-06-22 2021-09-01 德商梅茲製藥有限兩合公司 Botulinum toxin prefilled syringe system, kit having the same and use thereof
EP3290437A1 (en) 2016-08-31 2018-03-07 Merz Pharma GmbH & Co. KGaA Novel recombinant clostridial neurotoxins with decreased duration of effect
EP3312193A1 (en) 2016-10-19 2018-04-25 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with accelerated onset of effect
WO2018096169A1 (en) * 2016-11-28 2018-05-31 C-Lecta Gmbh Trehalose phosphorylase
WO2018233813A1 (en) 2017-06-20 2018-12-27 Merz Pharma Gmbh & Co. Kgaa NOVEL RECOMBINANT BOTULINUM TOXINS WITH INCREASED DURATION
EP3649143B1 (en) 2017-07-06 2022-08-31 Merz Pharma GmbH & Co. KGaA Novel recombinant botulinum neurotoxins with increased duration of effect
WO2019158745A1 (en) * 2018-02-16 2019-08-22 Bontana Therapies Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
JP7365707B2 (en) 2018-03-12 2023-10-20 コナゲン インコーポレイテッド Production of steviol glycosides rebaudioside J and rebaudioside N by biosynthesis
JP2021516682A (en) * 2018-03-13 2021-07-08 スミヴェット ビー．ブイ．Ｓｍｉｖｅｔ Ｂ．Ｖ． Single domain antibody that binds to tetanus neurotoxin
US10751399B2 (en) * 2018-03-20 2020-08-25 Cho Pharma Usa, Inc. Chimeric antigen receptors that bind to SSEA4 and uses thereof
WO2019211969A1 (en) * 2018-05-02 2019-11-07 天野エンザイム株式会社 Modified esterase and application therefor
CN108588087B (en) * 2018-05-16 2022-06-03 南京农业大学 Gene GmLecRK-R for improving disease resistance of plants and application thereof
US11535836B2 (en) * 2018-12-21 2022-12-27 Fornia Biosolutions, Inc. Variant G6P G7P glucoamylase compositions and methods
CN109998055B (en) * 2019-04-09 2022-03-25 黑龙江省科学院大庆分院 Hemp seed antioxidant polypeptide chewable tablet and preparation method thereof
CN110100945B (en) * 2019-05-05 2022-05-03 黑龙江省科学院大庆分院 Hemp blood fat reducing peptide composition and application thereof
CN114391046A (en) * 2019-06-21 2022-04-22 苏州晶睿生物科技有限公司 Method and kit for detecting African swine fever virus
CN110295150A (en) * 2019-07-17 2019-10-01 天津润德生物科技有限公司 A kind of gland dependovirus virus recombinant plasmid, recombinant virus and construction method
CN110540996B (en) * 2019-08-29 2022-01-28 华中农业大学 Procambarus clarkii i-type lysozyme gLysi2 gene, gLysi2 protein coded by same and application thereof
KR20220074917A (en) * 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 HBV vaccines and methods of treating HBV
CN110643616A (en) * 2019-10-22 2020-01-03 云南省烟草农业科学研究院 Cloning and application of tobacco nicotine synthesis regulation gene NtERF91
TW202140513A (en) * 2020-02-22 2021-11-01 日商Ｊｃｒ製藥股份有限公司 Human transferrin receptor binding peptide
CN112540178B (en) * 2020-08-06 2023-12-19 武汉天德生物科技有限公司 Immunohistochemical kit for detecting early senile dementia and use method thereof
CN112662644B (en) * 2021-01-19 2022-04-22 华南理工大学 Diglycerol phosphate phosphodiesterase mutant and application thereof
CN113899907B (en) * 2021-09-07 2023-06-27 中国农业科学院油料作物研究所 Method for efficiently screening aflatoxin green prevention and control materials in one step and application thereof
CN115109759B (en) * 2022-06-24 2024-05-03 浙江工业大学 Carbonyl reductase LsCR mutant, engineered bacteria and their application in asymmetric reduction of carbonyl compounds to prepare chiral alcohols
CN115944721B (en) * 2022-12-14 2025-11-25 内蒙古华希生物科技有限公司 An immune composition, its preparation method and application
CN117741160B (en) * 2023-12-21 2024-07-12 汉王科技股份有限公司 Use of olfactory receptors for the recognition of ethanol and method for detecting ethanol

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6903187B1 (en) * 2000-07-21 2005-06-07 Allergan, Inc. Leucine-based motif and clostridial neurotoxins
US7491799B2 (en) * 2000-07-21 2009-02-17 Allergan, Inc. Modified botulinum neurotoxins
US20020127247A1 (en) * 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
DE10333317A1 (en) 2003-07-22 2005-02-17 Biotecon Therapeutics Gmbh Formulation for protein medicines without the addition of human serum albumin (HSA)
US7172764B2 (en) * 2003-11-17 2007-02-06 Allergan, Inc. Rescue agents for treating botulinum toxin intoxications
WO2006011966A1 (en) * 2004-06-30 2006-02-02 Allergan, Inc. Optimizing expression of active botulinum toxin type e
US20060004334A1 (en) 2004-06-30 2006-01-05 Kimberly-Clark Worldwide, Inc. Stabilized absorbent structures
US7879341B2 (en) 2004-07-26 2011-02-01 Merz Pharma Gmbh & Co. Kgaa Therapeutic composition with a botulinum neurotoxin

Also Published As

Publication number Publication date
EP2449101B1 (en) 2018-10-10
CN102471765A (en) 2012-05-23
KR20120104140A (en) 2012-09-20
US9193771B2 (en) 2015-11-24
US20120107362A1 (en) 2012-05-03
JP2012531191A (en) 2012-12-10
RU2012103376A (en) 2013-08-10
KR20170016529A (en) 2017-02-13
IL216414A0 (en) 2012-02-29
MX352265B (en) 2017-11-16
AU2010267963B2 (en) 2015-09-24
CA2763692A1 (en) 2011-01-06
WO2011000929A1 (en) 2011-01-06
HK1171246A1 (en) 2013-03-22
ES2693705T3 (en) 2018-12-13
JP6059986B2 (en) 2017-01-11
KR101818895B1 (en) 2018-01-15
AU2010267963A1 (en) 2011-12-22
JP2015231378A (en) 2015-12-24
BRPI1014253A2 (en) 2016-04-12
RU2582266C2 (en) 2016-04-20
EP2449101A1 (en) 2012-05-09
US20170072030A1 (en) 2017-03-16
MX2011013014A (en) 2012-01-27
US9511114B2 (en) 2016-12-06
US20140045760A1 (en) 2014-02-13
CN102471765B9 (en) 2016-07-27
US8586329B2 (en) 2013-11-19
IL216414A (en) 2016-08-31
US9827298B2 (en) 2017-11-28
CN102471765B (en) 2016-05-11
US20160030511A1 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IN2012DN00733A (en)
MX2014005544A (en) Neurotoxins exhibiting shortened biological activity.
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
MY161268A (en) PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME
MX374682B (en) 4-1BB BINDING MOLECULES.
MX2014009909A (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen.
MX2011013457A (en) Novel chemokine binding polypeptides capable of inhibiting the course of autoimmunity, inflammation and cancer.
ATE548381T1 (en) MODIFIED ERYTHROPOIETIN (EPO) POLYPEPTIDES WITH INCREASED PROTEASE RESISTANCE AND PHARMACEUTICAL COMPOSITIONS THEREOF
WO2010099477A3 (en) Polypeptide structural motifs associated with cell signaling activity
EA201171148A1 (en) ANTI-TELE-ANTAGONIST, SPECIFIC FOR THE ALPHA-4-BETA-7 HETERODIMER
MX2011013903A (en) Chimeric fgf19 polypeptides and uses thereof.
PH12012500771A1 (en) Human il-23 antigen binding proteins
WO2011123683A3 (en) Protease activated cytokines
MX2014005546A (en) Albumin binding antibodies and binding fragments thereof.
ATE512980T1 (en) POLYPEPTIDES WITH BETA-GLUCOSIDASE ACTIVITY AND POLYNUCLEOTIDES CODING THESE
WO2010099219A3 (en) Designer ligands of tgf-beta superfamily
AU2012298537A8 (en) Bispecific T cell activating antigen binding molecules
EP4276180A3 (en) Clostridium histolyticum enzyme
EA201590195A1 (en) DNA CODED LIBRARIES CONTAINING LINKS TO ENCODATING OLIGONUCLEOTIDE, NOT AVAILABLE FOR POLYMERASE READING
WO2011002977A3 (en) Genetically encoded photomanipulation of protein and peptide activity
PH12016500275B1 (en) Antibodies
EA201590162A1 (en) OspA MUTANT FRAGMENTS AND RELATED METHODS AND APPLICATIONS
WO2013052946A3 (en) Genetically encoded biosensors
SG191060A1 (en) Robo1-fc fusion protein for use in the treatment of hepatocarcinoma